LUNGCOVID: SARS-CoV-2 Infection in Patients With Thoracic Tumors - Multicenter Observational Study in Portugal

ABSTRACT

Introduction: Since the beginning of the COVID-19 pandemic, health care system was readjusted and thoracic cancer patients with COVID-19 were studied in international registries. In patients with malignant thoracic neoplasms the differential diagnosis is complex, due to the location of the disease and symptoms related to cancer. Age, smoking status, comorbidities, previous corticotherapy treatment, performance status and stage of thoracic malignancies have been described as prognostic factors. Some registries and series of COVID-19 in thoracic malignancy patients reported mortality rates of 26% (CCC-19), 32% (TERAVOLT), 39% (UKCCMP) and even 47% (Dutch Oncology COVID-19 Consortium). A national survey on the impact of COVID-19 in lung cancer patients' treatment has been presented by the Portuguese Lung Cancer Study Group. However, a national study of COVID-19 patients with thoracic malignancies has not been done. Objectives: To access the frequency and severity of COVID-19 in Portuguese patients with thoracic malignancies, and to study clinical manifestations, intensive care admission and factors associated with a worst outcome. Methods: LUNGCOVID is a multicenter national observational study. Patients with primary thoracic malignancy, age 18-years-old and SARS-CoV-2 infection diagnosed by reverse-transcriptase polymerase chain reaction or antigenic test since March 2020, will be eligible. Clinicopathological characteristics will be accessed by reviewing medical records. The variables to be studied are age, sex, performance status, smoking habits, presence of comorbidities, previous corticotherapy treatment, factors related to the underlying cancer disease (stage of the disease, histological type), treatments, previous chest radiotherapy, oncologic systemic treatment, COVID-19 symptoms, need of intensive care admission and survival. Results: Section not applicable Conclusion: Section not applicable. Keywords SARS-CoV-2, thoracic tumors, Outcome: